© 2020 MJH Life Sciences and HCPLive. All rights reserved.
© 2020 MJH Life Sciences™ and HCPLive. All rights reserved.
September 25, 2020
Mepolizumab will be used to treat both adult and pediatric patients with HES for at least 6 months without an identifiable non-hematologic secondary cause.
A study found that patients more commonly self-reported unintentional barriers to treatment adherence—such as forgetfulness and external influences—than intentional ones.
The treatment could also be used for Alzheimer disease and mid-stage Huntington disease for patients who suffer from greater cognitive deficits.
September 24, 2020
These discrepancies are more pronounced in young, adolescent females and older adolescent males.
September 22, 2020
Gene addition and editing strategies have potential of curing sickle cell disease and transfusion-dependent thalassemia, but there are still many obstacles that must be overcome.
September 17, 2020
Interview results show patients can generally recall giving transfusion consent, but not information on the procedures benefits and risks.
The methodologies used to screen sickle cell disease are also able to detect alpha-thalassemia, which is currently not a core condition of the United States Recommended Uniform Screening Panel.
September 05, 2020
September 01, 2020
Azacytidine 300 mg tablets, CC-486 is earmarked for AML patients who achieved their first complete remission following intensive induction chemotherapy.
August 19, 2020
Valoctocogene roxaparvovec would be the first ever approved gene therapy to treat patients with hemophilia A.